| P2093 | author name string | Julia Abelson | |
| | Patricia A Collins | |
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Print media framing of the environmental movement in a Canadian forestry debate. | Q30328174 |
| | What is newsworthy? Longitudinal study of the reporting of medical research in two British newspapers | Q33890739 |
| | Sensationalism in the media: when scientists and journalists may be complicit collaborators. | Q34348144 |
| | Media coverage of scientific meetings: too much, too soon? | Q34662004 |
| | Science writers' reactions to a medical "breakthrough" story | Q34734655 |
| | Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. | Q34963164 |
| | The History of Breast Cancer Advocacy | Q35114117 |
| | Health and media: an overview | Q35200164 |
| | Sucked into the Herceptin maelstrom | Q35573765 |
| | The Common Drug Review: a NICE start for Canada? | Q36281334 |
| | Media reporting on research presented at scientific meetings: more caution needed. | Q36503764 |
| | Do the print media "hype" genetic research? A comparison of newspaper stories and peer-reviewed research papers | Q37729130 |
| | The role of the media in steering public opinion on healthcare issues | Q40609020 |
| | NICE approves trastuzumab for early stage breast cancer | Q42407958 |
| | Trastuzumab for early breast cancer raises important issues | Q42618806 |
| | Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum | Q42681112 |
| | How well do Canadian media outlets convey medical treatment information?: Initial findings from a year and a half of media monitoring by Media Doctor Canada | Q42729217 |
| | Patient demand and politics push Herceptin forward | Q42939087 |
| | Impact of the media and the internet on oncology: survey of cancer patients and oncologists in Canada | Q45714095 |
| | What's the rush? The dissemination and adoption of preliminary research results | Q46990666 |
| | Are we expecting too much from print media? An analysis of newspaper coverage of the 2002 Canadian healthcare reform debate | Q50116382 |
| | Media coverage of managed care: is there a negative bias? | Q52900469 |
| | Coverage by the news media of the benefits and risks of medications. | Q53520692 |
| | Different frames, different fears: communicating about chlorinated drinking water and cancer in the Canadian media | Q73035038 |
| | Press releases: translating research into news | Q74208430 |
| | The media matter: a call for straightforward medical reporting | Q75391880 |
| | The media and public reaction to genetic research | Q77651702 |
| | Monitoring the quality of medical news reporting: early experience with media doctor | Q81054616 |
| | Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer | Q81241467 |
| | Trastuzumab in the treatment of breast cancer | Q81374982 |
| | Herceptin and early breast cancer: a moment for caution | Q81486833 |
| | Trastuzumab trials steal show at ASCO meeting | Q81852806 |
| P433 | issue | 3 | |
| P921 | main subject | newspaper | Q11032 |
| P304 | page(s) | e113-28 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Healthcare Policy | Q15763732 |
| P1476 | title | Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage | |
| P478 | volume | 4 | |